Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05024773 · ClinicalTrials.gov registry record · Phase 3
Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)
A Phase 3 study of Bladder Carcinoma in Situ (CIS), sponsored by Fidia Farmaceutici s.p.a..
- Recruiting
- Registry status
- Phase 3
- Development phase
- 112
- Enrollment target
- 20
- Study locations
NCT05024773: Recruiting Phase 3 study of Bladder Carcinoma in Situ (CIS), sponsored by Fidia Farmaceutici s.p.a..
NCT05024773 is a Phase 3 study of Bladder Carcinoma in Situ (CIS) that is actively recruiting participants, run by Fidia Farmaceutici s.p.a.. The registered enrollment target is 112 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05024773, a Phase 3 study of Bladder Carcinoma in Situ (CIS), is actively recruiting participants, sponsored by Fidia Farmaceutici s.p.a..
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 112 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unwilling or unfit to undergo radical cystectomy. After providing written informed consent (in presence of an Independent Witness, if applicable), patients will receive an induction therapy consisting of 12 weekly intravesical instillations of ONCOFID-P-B (induction phase). Patients with residual CIS at the end of induction treatment are eligible to enter a re-induction course of therapy (reinduction phase). Patients with stable disease by Investigator assessment defined as neither increased or decreased in extent or severity compared to baseline, are not eligible for re-induction therapy. Patients who achieve a complete resonde (CR) at the end of the induction or re-induction phase enter in the maintenance phase and receive monthly intravesical instillations of ONCOFID-P-B for an additional 12 monsthe or untile recurrence of CIS/HG Ta-T1 or progression to MIBC or extravesical disease. Patients who do not achieve a CR at the end of induction or re-induction phase, will discontinue investigational treatement and are followed up until month 48 from induction or re-induction start, or until a new antitumor therapy is initiated, wichever occurs first. Tumor response is evaluated by cystoscopy, cytology and biopsy at the end of the induction and re-induction phases and at Safety Follow Up Visit (SFUV). During the maintenance/follow-up period, tumorresponse is evaluated by cystoscopy and cytology every 3 months for up to 24 months from induction or re-induction start, and then every 6 months for an additional 2 years (long-term follow-up). Tumor biopsies are performed in case of of positive cystoscopy and/or cytology. Random biopsies are to be performed at 6, 12 and 18 months af
Primary Outcome
CRR calculated as the proportion of patients achieving a CR at any time within 24 months after induction or re-induction start. CRR will be based on central assessment of response
Conditions Studied
Interventions
- DRUG ONCOFID P-B (PACLITAXEL-HYALURONIC ACID)
Study Locations (20)
Other
- CHU Bordeaux -Hopital Pellegrin - Bordeaux
- CHU de Clermont-Ferrand - Hopital Gabriel Montpied - Clermont-Ferrand
- CHU de Lille - Hopital Claude Huriez - Lille
- Institute Paoli-Calmettes - Marseille
- AP-HP Hopital Bichat-Claude Bernard - Paris
- AP-HP Hopital Tenon - Paris
- Centre Hospitalier Universitaire Poitiers - Poitiers
- Humanitas Gavazzeni - Bergamo
- IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant'Orsola - Bologna
- Istituto Oncologico Veneto-I.R.C.C.S.-Ospedale San Giacomo - Castelfranco Veneto
- Azienda Ospedaliero-Universitaria Careggi - Florence
- ASL Lecce- Ospedale Vito Fazzi - Lecce
- Istituto Clinico Humanitas - Milan
- IRCSS Ospedale San Raffaele - Milan
Arizona
- Banner Health- MD Anderson Cancer Center - Gilbert
Louisiana
- Ochsner Clinic Foundation - New Orleans
Maryland
- Johns Hopkins Kimmel Cancer Center - Baltimore
Minnesota
- University of Minnesota - Minneapolis
Ohio
- TriState Urologic Services PSC Inc. dba The Urology Group - Cincinnati
South Carolina
- Medical University of South Carolina (MUSC) - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 112 participants |
| Start Date | 2022-12-29 |
| Est. Completion | 2027-11 |
| Phase | Phase 3 |
What NCT05024773 shows while recruiting
NCT05024773 is an interventional study that assigns participants to a tested intervention. The registered 112 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Bladder Carcinoma in Situ (CIS) appearing as the primary indexed condition, and to 1 intervention - of which ONCOFID P-B (PACLITAXEL-HYALURONIC ACID) is the first listed.
NCT05024773 names 20 study sites across 7 states, led by Other, Arizona, Louisiana.
Frequently Asked Questions
What is clinical trial NCT05024773 about?
NCT05024773 is a clinical study titled "Study of ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID)". This is a phase III, single-arm, multicenter, international study to assess the efficacy and safety of ONCOFID-P-B following intravesical instillation in adult patients with histologically and cytologically confirmed CIS, with or without concomitant Ta-T1, who are unresponsive to BCG therapy and unw...
What is the current status of trial NCT05024773?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 112 participants. The study started on 2022-12-29. Estimated completion is 2027-11.
What conditions does trial NCT05024773 study?
This clinical trial studies the following conditions: Bladder Carcinoma in Situ (CIS).
What interventions are being tested in trial NCT05024773?
The interventions under investigation include: ONCOFID P-B (PACLITAXEL-HYALURONIC ACID) (DRUG).
Who is sponsoring clinical trial NCT05024773?
This trial is sponsored by Fidia Farmaceutici s.p.a., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05024773 being conducted?
This trial has 20 study locations across Arizona, Louisiana, Maryland, Minnesota, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05024773's enrollment target sits among peer trials
112 1653rd of 2000 higher than 346 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04511013 · 112 participants · Phase 2
A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- NCT04551560 · 112 participants · NA
Stress and Congestive Heart Failure
- NCT04872166 · 112 participants · Phase 1
A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
- NCT05157620 · 112 participants · NA
Exercise-based Program for Rehabilitation of Veterans With Severe Mental Illness
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI